Barrow Neurological Institute, Phoenix, AZ, USA; 11 Long Island Brain Tumor Center at Neurological Surgery, P.C., Lake Success, NY, USA; 12 University of Washington School of Medicine, Seattle, WA, USA; 13 Celldex Therapeutics, Inc., Hampton, NJ, USA BACKGROUND: EGFRvIII, a constitutively active EGFR deletion driver mutation, is associated with poor long-term survival in glioblastoma (GB). The investigational vaccine rindopepimut consists of an EGFRvIII-specific peptide sequence conjugated to keyhole limpet hemocyanin (KLH), delivered intradermally with GM-CSF. Three phase II studies in newly diagnosed, resected, EGFRvIII+ GB demonstrated encouraging progression-free survival (PFS), overall survival (OS) and safety. METHODS: In the Phase II "ReACT" study, 73 bevacizumab (BV)-naïve pts in 1st or 2nd relapse with EGFRvIII+ GB were randomized 1:1 to BV plus double-blinded injection of rindopepimut or control (KLH). Endpoints: 6-month PFS (PFS6; primary; target a ¼ 0.2 by 1-sided chi-square test), objective response rate (ORR), PFS, OS and safety. RESULTS: Primary rindopepimut toxicity is Grade 1-2 injection site reaction. For rindopepimut + BV vs. KLH + BV (per centralized review; RANO criteria): PFS6 ¼ 28% (10/36) vs. 16% (6/37) (p ¼ 0.116); ORR ¼ 30% (9/30) vs. 18% (6/34). Cessation of steroids . 2 months: 44% (8/18) vs 21% (4/19), .6 months: 33% (6/18) vs. 0. Median (95% CI) OS ¼ 11.6 (10.0, 16.2) vs. 9.3 (7.1, 11.3) months (HR ¼ 0.57 [0.33, 0.98], p ¼ 0.039). 9 vs 6 pts remain in follow-up; 6 vs. 2 are progression-free. OS analyses adjusted for various prognostic factors consistently favor rindopepimut. Rindopepimut induced robust anti-EGFRvIII titers (1:12,800-1:6,553,600) in 80% of pts. Antibodies, predominantly IgG1 isotype, mediate killing of EGFRvIII+ tumor cells through ADCC and CDCC in vitro. Within the rindopepimut arm, peak titer (≥1:12,800 at any time) and rapid titer generation (≥1:12,800 by Day 57) were associated with prolonged OS (HR ¼ 0.16, p ¼ ,0.0001 and HR ¼ 0.59, p ¼ 0.182, respectively). Evaluation of humoral response quality, HLA typing vs. outcome, and survival follow-up continue. In an additional cohort of BV-exposed pts (n ¼ 53), four pts experienced objective tumor response. CONCLUSIONS: Rindopepimut induces potent EGFRvIII-specific immune response and tumor regression, and appears to significantly prolong survival when administered with BV, in pts with relapsed GB.
